Business Context and Reporting Period
This Form 8-K is a current report filed by Shuttle Pharmaceuticals Holdings, Inc. on September 11, 2025. The company is incorporated in Delaware and its common stock trades on The Nasdaq Stock Market LLC under the symbol SHPH. The registrant is classified as an emerging growth company.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
The material change disclosed in this filing is the resignation of Joseph Tung as a director of the company, effective September 11, 2025. The company explicitly states that this resignation was not the result of any disagreement that would require disclosure under Item 5.02(a) of Form 8-K.
Guidance, Outlook, and Management Commentary
The filing contains no guidance, outlook, or management commentary regarding future business operations or financial performance. The report is signed by Christopher Cooper, who is identified as the Interim Chief Executive Officer.
Key Facts for Investor Verification
- Joseph Tung resigned from the Board of Directors on September 11, 2025.
- The resignation was not due to any disagreement with the company.
- Christopher Cooper is currently serving as Interim Chief Executive Officer.
- No financial data or operational metrics are included in this specific filing.